- Vinod H Srihari, assistant professor,
- T Warren Lee, assistant professor
- 1Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
- Correspondence to: V H Srihari vinod.srihari{at}yale.edu
- Accepted 13 March 2008
A 45 year old man with schizophrenia began experiencing auditory hallucinations at the age of 25. These were well controlled for several years by a monthly intramuscular injection of haloperidol decanoate. One year after he switched to oral haloperidol, the intensity of the hallucinations increased and included a voice commanding him to end his life. Concerns for his safety led to a brief admission to psychiatric hospital. When he had to return to hospital within a month, the inpatient psychiatrist inferred a loss of response to haloperidol and encouraged the patient to switch to clozapine. Six months later he was brought to an emergency department in an acute confusional state after a clozapine overdose. The drug was discontinued and his mental status improved rapidly, but investigation of acute dyspnoea showed bilateral pulmonary emboli. The patient was not overweight and had no history of recent surgery, trauma to the legs, or malignancy, but he was a heavy smoker. Laboratory tests for hypercoagulable states had negative results. He was treated with intravenous heparin and then oral warfarin and was transferred to a psychiatric unit for resumption of treatment with clozapine.
I (VHS) received a call from a physician in training who had admitted the patient to the psychiatric unit. She wondered about a possible association between clozapine and thromboembolism. I consulted with a colleague (TWL) who, like me, had not heard of this risk. The patient was expected to be in hospital for two more weeks, which gave us some time to consider alternative drugs.
Asking a question
The most pressing area of uncertainty was determining whether clozapine had anything to do with this patient’s pulmonary emboli and if so, whether alternative drugs posed less of a risk.1 We formulated a structured question: in a patient with schizophrenia who does not have any risk …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Ethical considerations
Published 14 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 14 February 2012
Re: Raised inflammatory markers
Published 14 February 2012
Re: Physical activity for cancer survivors: meta-analysis of randomised controlled trials
Published 14 February 2012
Smokefree cars in Wales: Laws are better
Published 14 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (8 responses)
Published 1 Feb 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012